Background

Hemangiopericytoma is a tumor originating from the vascular pericytes of Zimmermann. Most frequently it occurs in patients aged 40 and above with its main localization in the retroperitoneum, pelvis and lower extremities [1-3], however, it may occur at any age in almost any part of body [4]. One of the typical features of this tumor is that both metastasis and recurrence could become apparent even after several years in remission [5-7].

We report the case of a local recurrence and metastases in the retroperitoneum infiltrating the liver and diaphragm in a 61-year-old patient operated on due to a hemangiopericytoma of the greater omentum 18 years before.

Case presentation

A 61-year-old patient was admitted to the Department of Transplantation and General Surgery with a tumor diagnosed in the left lumbar and retroperitoneal space. Eighteen years before he had been operated for a tumor of the greater omentum with histopathological diagnosis hemangiopericytoma omenti maioris, until now with no recurrence nor distant metastases were found.

On admission the patient was in good general condition with left lumbar pain and a mobile tumor in this area. Abdominal ultrasonography (US) and computed tomography (CT) revealed a retroperitoneal space tumor with suspected infiltration of the segment VII of the liver and diaphragm.

Laboratory investigation showed no abnormalities. The patient was qualified for surgical treatment. A tumor of 5 cm in diameter in the greater omentum tightly adjacent to a transverse colon (figure 1), a tumor of 1 cm in diameter in the jejunal mesentery (figure 2, arrow) and a tumor of
12 cm in diameter located in the retroperitoneal space and infiltrating the diaphragm and the segment VII of the liver were found. No other lesions were found in intraoperative US. The tumors of the greater omentum and of the jejunum mesentery were excised whereas the retroperitoneal space tumor was removed en bloc with the infiltrated part of the diaphragm and the segment VII of the liver (figure 3, and 4). The postoperative course proved uneventful. The patient was discharged from the hospital 7 days after the procedure in good general condition with a subsequent surgical follow-up recommended.

Histopathological examination of all the lesions showed haemangiopericytoma malignum. The patient remains under the Oncology Centre and our clinical follow-up and at present, 3 months after the procedure, is in good condition.

Discussion
Hemangiopericytomas represent less than 1% of all vascular neoplasms [8]. They are highly vascular, therefore could be revealed by angio-CT and angiography (for diagnosis, tumor size, relationship to other viscera, source of blood supply) as well as undergo preoperative transarterial embolization if necessary [3,5]. The tumors' medium size is 6.5 cm and they are encapsulated by a pseudocapsule [1,3]. There is no grading scale for hemangiopericytoma; its malignant potential is implied by histology and clinical behavior [5]. Hypervascularity is a contraindication to a biopsy, therefore a histopathological diagnosis is established after an excision of the lesion. Potentially malignant tumors are characterized by 1 mitotic figure per 10 high-power field and moderate anaplasia. According to McMaster et al., 25 of 32 (78%) malignant tumors, 6 of 16 (37.5%) borderline lesions and no benign tumors metastasised [6].

Metastases occur by hematogenous and lymphogenous routes affecting mainly the lung, liver, bones and regional lymph nodes [1,3,9,10]. Metastasis to pleura have also been reported [11]. Metastases occurring many years after excision of a primary lesion is typical of hemangiopericytoma.
Hemangiopericytoma: In our case it was 18 years. Multiple hepatic and bone metastases 12 years after an excision of a nose tumor have been reported [12]. McMaster et al., reveal that metastases became apparent in 11% of patients with malignant tumors and 7% with borderline tumors after 5 years' remission [6]. Local recurrence is also common and precedes metastases in more than 2/3 of cases [1,13]. In two cases presented by Panda et al., it occurred after 4 months in one patient and 22 years in another [7]. Therefore long-term follow-up is essential [6]. Hypercellularity, mitotic activity, anaplasia, necrosis and hemorrhage are reported to be associated with higher malignant potential [13].

Surgical resection with subsequent radiotherapy remains the treatment of choice for hemangiopericytoma. The role of preoperative angiography and tumor embolization is also emphasized in literature [3,5,6]. Survival rates vary: In a review of 106 cases of hemangiopericytoma, Enzinger et al., reported 70% 10-year survival, whereas it was 50% 5-year survival according to other authors [1,10].

Late recurrence is common in other malignancies as well. According to Shen et al., in primary cutaneous melanoma the mean disease-free interval after surgery was 182 months [14] whereas Briele et al., report seven patients in whom local or regional recurrence occurred 11 to 23 years after first treatment of melanoma [15]. Another neoplasm after a treatment of which long-term follow-up is essential is medulloblastoma as recurrences after the Collins’ risk period (i.e. age of a patient plus 9 months) have been noticed [16,17]. The average follow-up in case of rectal cancer surgical treatment is 2 years whereas research shows that local recurrence can become evident even after 5.8 years and systemic recurrence after 7.9 years [18].

Continued long-term follow-up in patients treated for above mentioned malignancies proves beneficial [15,17,19].

**Conclusion**

Every patient treated due to a malignant or borderline hemangiopericytoma should be under long-term oncological follow-up as the risk of recurrence and distant metastases even after many years is very high.

**Competing interests**

The authors declare that they have no competing interests.

**Authors’ contributions**

MS conceived the idea for the study, participated in its design and coordination, analyzed the data, wrote the first draft of the manuscript.

IP conducted the literature review, was involved in data collection, analyzed the data, helped to draft the manuscript.

ZW participated in the study design and coordination, helped to draft the manuscript.

All authors read and approved the final version of the manuscript.

**Acknowledgements**

The written consent was obtained from the patient for publication of this case report.

**References**

1. Enzinger FM, Smith BH: Hemangiopericytoma. An analysis of 106 cases. Hum Pathol 1976, 7:61-82.
2. Smith RT, Small WC, Mansour K: Case report: hemangiopericytoma of the oesophagus. Br J Radiol 1995, 68:1031-1033.
3. Goldman S, Davidson A, Neal J: Retropertitoneal and pelvic hemangiopericytomas: clinical, radiologic, and pathologic correlation. Radiology 1988, 168:13-17.
4. Stout AP: Tumors featuring pericytes. Glomus tumor and hemangiopericytoma. Lab Invest 1956, 5:217-223.
5. Craven JP, Quigley TM, Bolen JW, Raker EJ: Current management and clinical outcome of hemangiopericytomas. Am J Surg 1992, 163:490-493.
6. McMaster MJ, Soule EH, Ivins JC: Hemangiopericytoma. A clinicopathologic study and long-term follow up of 60 patients. Cancer 1975, 36:2232-2244.
7. Panda A, Dayal Y, Singhal V, Pattnaik NK: Hemangiopericytoma. Br J Ophth 1984, 68:124-127.
8. Sabini P, Josephson GD, Yung RT, Dollitsky JN: Hemangiopericytoma presenting as a congenital midline nasal mass. Arch Otolaryngal Head Neck Surg 1998, 124:202-204.
9. Binder SC, Wolfe Hj, Deterling RA Jr: Intraabdomnal hemangiopericytoma: report of four cases and review of the literature. Arch Surg 1973, 107:516-543.
10. Felix EL, Wood DK, Das Gupta TK: Tumors of the retropertitoneum. In Current problems in cancer Edited by: Hickey RC, Clark RL, Benfield JR, Hurter R, Moertel CC, Shingleton W. Chicago: Year Book Medical; 1981:1-47.
11. Pandey M, Ahmed MI, Abraham EK, Sebastian P: Recurrent Hemangiopericytoma metastasizing to pleura: A case report. Indian J Surg 2002, 64:183-185.
12. Dempke W, Furusian N: Unusual course of hemangiopericytoma. Med Klin (Munich) 1998, 93:726-728.
13. Pandey M, Kothari KC, Patel DD: Hemangiopericytoma. Current status, diagnosis and management. Eur J Surg Oncol 1997, 23:282-285.
14. Shen P, Guenther JM, Wanek LA, Morton DL: Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences? Ann Surg Oncol 2000, 7:114-119.
15. Briele HA, Beattie CW, Ronan SG, Chaudhuri PK, Das Gupta TK: Late recurrence of cutaneous melanoma. Arch Surg 1983, 118:800-803.
16. King GA, Sagerman RH: Late recurrence in medulloblastoma. Am J Roentgenol Radium Ther Nucl Med 1975, 123:7-12.
17. Nishio S, Morioka T, Takeshita I, Fukui M: Medulloblastoma: Survival and late recurrence after the Collins' risk period. Neurosurg Rev 1997, 20:245-249.
18. Moore E, Heald RJ, Cecil TD, Sharpe GD, Sexton R, Moran BJ: Almost all five year disease free survivors are cured following rectal cancer surgery, but longer term follow-up detects some late local and systemic recurrences. Colorectal Dis 2005, 7:403-5.
19. Koh HK, Sober AJ, Fitzpatrick TB: Late recurrence (beyond ten years) of cutaneous malignant melanoma. Report of two cases and a review of the literature. JAMA 1984, 251:1859-1862.